These findings not only introduce an effective target for IDO1 interference but also deepen our understanding of the mechanism by which tumor cells architect the immunosuppressive TME through self-reinforcement of metabolic immune checkpoint signaling. The gene discussed is IDO1; the disease is neoplasm.